147 related articles for article (PubMed ID: 16033830)
1. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.
Mikhail M; Velazquez E; Shapiro R; Berman R; Pavlick A; Sorhaindo L; Spira J; Mir C; Panageas KS; Polsky D; Osman I
Clin Cancer Res; 2005 Jul; 11(14):5153-7. PubMed ID: 16033830
[TBL] [Abstract][Full Text] [Related]
2. Loss of PTEN promotes tumor development in malignant melanoma.
Stahl JM; Cheung M; Sharma A; Trivedi NR; Shanmugam S; Robertson GP
Cancer Res; 2003 Jun; 63(11):2881-90. PubMed ID: 12782594
[TBL] [Abstract][Full Text] [Related]
3. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
5. Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth.
Lee JS; Choi YD; Choi C; Lee MC; Park CS; Min KW
Anal Quant Cytol Histol; 2005 Aug; 27(4):202-10. PubMed ID: 16220831
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome.
Peiró G; Lohse P; Mayr D; Diebold J
Am J Clin Pathol; 2003 Jul; 120(1):78-85. PubMed ID: 12866376
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
[TBL] [Abstract][Full Text] [Related]
8. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
9. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth.
Shin Lee J; Seok Kim H; Bok Kim Y; Cheol Lee M; Soo Park C
J Surg Oncol; 2003 Nov; 84(3):166-72. PubMed ID: 14598361
[TBL] [Abstract][Full Text] [Related]
10. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H; Goel V; Wu H; Yang G; Haluska FG
J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
[TBL] [Abstract][Full Text] [Related]
11. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.
Halvorsen OJ; Haukaas SA; Akslen LA
Clin Cancer Res; 2003 Apr; 9(4):1474-9. PubMed ID: 12684422
[TBL] [Abstract][Full Text] [Related]
12. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
13. Deregulated Akt3 activity promotes development of malignant melanoma.
Stahl JM; Sharma A; Cheung M; Zimmerman M; Cheng JQ; Bosenberg MW; Kester M; Sandirasegarane L; Robertson GP
Cancer Res; 2004 Oct; 64(19):7002-10. PubMed ID: 15466193
[TBL] [Abstract][Full Text] [Related]
14. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
15. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
16. Conference report - apoptosis - a graceful death: highlights from the 2003 Annual Meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC.
Mariani SM
MedGenMed; 2003 Oct; 5(4):4. PubMed ID: 14745351
[No Abstract] [Full Text] [Related]
17. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy.
Kanamori Y; Kigawa J; Itamochi H; Sultana H; Suzuki M; Ohwada M; Kamura T; Sugiyama T; Kikuchi Y; Kita T; Fujiwara K; Terakawa N
Int J Cancer; 2002 Aug; 100(6):686-9. PubMed ID: 12209607
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.
Sano T; Lin H; Chen X; Langford LA; Koul D; Bondy ML; Hess KR; Myers JN; Hong YK; Yung WK; Steck PA
Cancer Res; 1999 Apr; 59(8):1820-4. PubMed ID: 10213484
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
20. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma.
Uegaki K; Kanamori Y; Kigawa J; Kawaguchi W; Kaneko R; Naniwa J; Takahashi M; Shimada M; Oishi T; Itamochi H; Terakawa N
Oncol Rep; 2005 Aug; 14(2):389-92. PubMed ID: 16012720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
